BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 28222412)

  • 21. Robotic total thyroidectomy with modified radical neck dissection via unilateral retroauricular approach.
    Byeon HK; Holsinger FC; Tufano RP; Chung HJ; Kim WS; Koh YW; Choi EC
    Ann Surg Oncol; 2014 Nov; 21(12):3872-5. PubMed ID: 25227305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy.
    Lang BH; Ng SH; Lau LL; Cowling BJ; Wong KP; Wan KY
    Thyroid; 2013 Sep; 23(9):1087-98. PubMed ID: 23402640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
    Suman P; Wang CH; Abadin SS; Block R; Raghavan V; Moo-Young TA; Prinz RA; Winchester DJ
    Endocr Pract; 2016 Jul; 22(7):822-31. PubMed ID: 27018620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preferential Use of Total Thyroidectomy without Prophylactic Central Lymph Node Dissection for Early-Stage Papillary Thyroid Cancer: Oncologic Outcomes in an Integrated Health Plan.
    Said M; Fujimoto M; Franken C; Woo S; Vuong B; Haigh PI
    Perm J; 2016; 20(4):15-251. PubMed ID: 27723445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Routine central lymph node dissection with total thyroidectomy for papillary thyroid cancer potentially minimizes level VI recurrence.
    Hall CM; Snyder SK; Maldonado YM; Lairmore TC
    Surgery; 2016 Oct; 160(4):1049-1058. PubMed ID: 27521047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcomes of central neck dissection for cN0 papillary thyroid carcinoma.
    Giordano D; Frasoldati A; Gabrielli E; Pernice C; Zini M; Castellucci A; Piana S; Ciarrocchi A; Cavuto S; Barbieri V
    Am J Otolaryngol; 2017; 38(5):576-581. PubMed ID: 28599790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Papillary thyroid carcinoma with exclusive involvement of a functioning recurrent laryngeal nerve may be treated with shaving technique.
    Lee HS; Kim SW; Park T; Nam GY; Hong JC; Lee KD
    World J Surg; 2015 Apr; 39(4):969-74. PubMed ID: 25446493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological pattern of lymph node recurrence of papillary thyroid cancer. Implications for surgery.
    Conzo G; Mauriello C; Docimo G; Gambardella C; Thomas G; Cavallo F; Tartaglia E; Napolitano S; Varriale R; Rossetti G; Fei L; Santini L
    Int J Surg; 2014; 12 Suppl 1():S194-7. PubMed ID: 24862675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Occult lymph node metastasis and risk of regional recurrence in papillary thyroid cancer after bilateral prophylactic central neck dissection: A multi-institutional study.
    Lee YC; Na SY; Park GC; Han JH; Kim SW; Eun YG
    Surgery; 2017 Feb; 161(2):465-471. PubMed ID: 27574773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recurrence of papillary thyroid carcinoma with lateral cervical node metastases: Predictive factors and operative management.
    Chéreau N; Buffet C; Trésallet C; Tissier F; Leenhardt L; Menegaux F
    Surgery; 2016 Mar; 159(3):755-62. PubMed ID: 26435440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment for microcarcinoma of the thyroid--clinical experience.
    Küçük NO; Tari P; Tokmak E; Aras G
    Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
    Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
    Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk-adapted management of papillary thyroid carcinoma according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low-risk patients?
    Ebina A; Sugitani I; Fujimoto Y; Yamada K
    Surgery; 2014 Dec; 156(6):1579-88; discussion 1588-9. PubMed ID: 25262223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma.
    Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ
    Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of Early Postoperative Unstimulated Thyroglobulin in Influencing Decision Making in Patients with Papillary Thyroid Carcinoma.
    McDow AD; Shumway CM; Pitt SC; Schneider DF; Sippel RS; Long KL
    Ann Surg Oncol; 2019 Nov; 26(12):4002-4007. PubMed ID: 31267301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of radioiodine after thyroid lobectomy in patients with differentiated thyroid cancer: does it change outcomes?
    Kiernan CM; Parikh AA; Parks LL; Solórzano CC
    J Am Coll Surg; 2015 Apr; 220(4):617-25. PubMed ID: 25667136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.
    Hughes DT; Miller BS; Cohen MS; Doherty GM; Gauger PG
    Ann Surg Oncol; 2014 May; 21(5):1647-52. PubMed ID: 24385210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment.
    Grigsby PW; Reddy RM; Moley JF; Hall BL
    Surgery; 2006 Dec; 140(6):1043-7; discussion 1047-9. PubMed ID: 17188155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?
    Wei L; Bai L; Zhao L; Yu T; Ma Q; Ji B
    World J Surg; 2019 May; 43(5):1256-1263. PubMed ID: 30684002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.